CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A Prospective, Non-Interventional Study of the Safety and Effectiveness of Cemiplimab in Immunocompromised/Immunosuppressed Patients With Advanced Cutaneous Squamous Cell Carcinoma at 2 Years’ Follow-Up. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s756, 2026. DOI: 10.25251/hex0h755. Disponível em: https://skin.dermsquared.com/skin/article/view/4093. Acesso em: 2 may. 2026.